RxDoctor Payments Data

Thomas Sargero, MD

Internal Medicine · Hamilton, OHNPI 1033104468

Payments from drug & device makers

$82,408in general payments, 2019–2025

Across 1,729 payments — averaging $47.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$29K
  • Lilly USA, LLC$16K
  • Johnson & Johnson$15K
  • AstraZeneca$3K
  • Novo Nordisk$3K
  • Medtronic$2K
  • plus $15K from 54 others

What the payments were for

  • Consulting fees$5,3446%
  • Speaking & faculty fees$44,96055%
  • Travel & lodging$4,1215%
  • Food & beverage$27,63134%
  • Education$3520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer120$28,997
Lilly USA, LLC114$15,830
Johnson & Johnson173$15,190
AstraZeneca(2 entities)112$3,220
Novo Nordisk156$2,589
Medtronic19$1,618
Amgen62$1,399
AbbVie(2 entities)112$1,109
Boehringer Ingelheim57$857
Astellas Pharma US Inc47$831
Corcept Therapeutics47$735
Amarin Pharma, Inc.50$698
Pfizer67$688
Novartis44$680
Sanofi-aventis U.S. LLC38$676
Merck44$600
Insulet Corporation35$593
Exact Sciences30$524
Sunovion Pharmaceuticals Inc.30$434
Xeris Pharmaceuticals, Inc.21$380
Nestle Healthcare Nutrition Inc.62$375
Radius Health, Inc.14$232
Teva Pharmaceuticals USA, Inc.13$229
Jazz Pharmaceuticals Inc.11$206
Otsuka America Pharmaceutical, Inc.16$193
Aimmune Therapeutics, Inc.27$193
Recordati_rare_diseases_inc.12$170
Valeritas, Inc.16$159
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$159
Sumitomo Pharma America, Inc.8$156
Avanir Pharmaceuticals, Inc.11$149
Daiichi Sankyo Inc.9$145
Biogen8$139
GSK9$133
Kowa Pharmaceuticals America, Inc.9$116
Mannkind Corporation6$110
Tandem Diabetes Care, Inc.6$110
Takeda Pharmaceuticals U.S.A., Inc.8$102
E.r. Squibb & Sons, L.L.C.7$99
Dexcom, Inc.4$95
Eisai Inc.6$94
Ironwood Pharmaceuticals, Inc6$88
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$87
Biohaven Pharmaceuticals, Inc.6$84
Bristol Myers Squibb1$83
Corium, LLC5$78
Esperion Therapeutics, Inc.6$77
Biohaven Pharmaceutical Holding Company Ltd.5$70
Grifols USA, LLC3$64
Paratek Pharmaceuticals, Inc.3$62
Phathom Pharmaceuticals, Inc.3$62
Lundbeck LLC4$61
Ascensia Diabetes Care US Inc.3$60
Neurocrine Biosciences, Inc.3$58
Evoke Pharma, Inc.3$54
Cequr Corporation1$52
Axsome Therapeutics, Inc.3$46
Acadia Pharmaceuticals Inc3$44
Abbott2$44
Zealand Pharma US, Inc.2$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,408 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$78,280
Medicare patients
122
Services billed
978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KorlymMifepristone26$804,454
OzempicSemaglutide298$390,666
XareltoRivaroxaban357$230,647
TrulicityDulaglutide214$224,997
FarxigaDapagliflozin Propanediol272$221,556
JardianceEmpagliflozin242$220,421
MounjaroTirzepatide94$121,913
KerendiaFinerenone102$120,467
EliquisApixaban172$99,206
AustedoDeutetrabenazine12$72,090
ForteoTeriparatide15$68,675
MyrbetriqMirabegron130$66,756
Tresiba Flextouch U-200Insulin Degludec86$66,059
LinzessLinaclotide104$63,121
EntrestoSacubitril/Valsartan91$57,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Corcept TherapeuticsKorlym$735$804,45426 claims
Novo NordiskOzempic, Rybelsus, Fiasp$2,589$461,294359 claims
Lilly USA, LLCTrulicity, Mounjaro, Forteo$15,830$415,585323 claims
AstraZenecaFarxiga, Breztri Aerosphere$3,220$259,053322 claims
Johnson & JohnsonXarelto, Invokana$15,190$256,594378 claims
Boehringer IngelheimJardiance$857$220,421242 claims
PfizerEliquis, Nurtec Odt, Abrysvo$688$130,693235 claims
BayerKerendia$28,997$120,467102 claims
AbbVieLinzess, Creon$1,109$81,669123 claims
Teva Pharmaceuticals USA, Inc.Austedo$229$72,09012 claims
Astellas Pharma US IncMyrbetriq$831$66,756130 claims
NovartisEntresto$680$57,69991 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Hamilton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →